Eli Lilly to invest $450M to expand manufacturing at Research Triangle Park

Eli Lilly announced plans to invest an additional $450M and create at least 100 new jobs to expand its manufacturing capacity at the company’s Research Triangle Park facility. The expansion includes additional parenteral filling, device assembly and packaging capacity to support an increased demand for Lilly’s incretin products that treat diabetes. Since 2020, Lilly has committed roughly $4B to new manufacturing facilities in North Carolina, including $1.7B for the development and expansion of its site at Research Triangle Park. The company anticipates initial production at Research Triangle Park to begin this year, with preparations for inspections by the FDA ongoing.